- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years to 22 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 362
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Interventions
- Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 22 more
- Conditions
- Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
- Interventions
- Omegaven® (fish oil triglycerides) Injectable Emulsion
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 366 Days to 46 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
- Conditions
- Leukemia
- Interventions
- clofarabine, cytarabine, methotrexate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Downey, California • Long Beach, California + 65 more
- Conditions
- Pediatric ALL
- Interventions
- Not listed
- Lead sponsor
- Life University
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Chippewa Falls, Wisconsin
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
- Interventions
- Cyclophosphamide, Fludarabine, Mesna, CliniMACS, CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
- Drug · Device · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
- Interventions
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 31 Days to 30 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Anemia, Healthy, Pediatric ALL
- Interventions
- Rad-67 Pulse oximeter
- Device
- Lead sponsor
- Masimo Corporation
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 447 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 7
- States / cities
- Burbank, California • Irvine, California • Lake Forest, California + 3 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Bortezomib, Vorinostat, Dexamethasone, Methotrexate, Imatinib mesylate
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
- Interventions
- Massage therapy, Standard of care
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Philadelphia, Pennsylvania
- Conditions
- B Cell, Acute Lymphoblastic Leukemia, Relapsed/Refractory
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 39 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pediatric ALL, Sepsis
- Interventions
- Pediatric eCART
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Leukemia
- Interventions
- loss of heterozygosity analysis, microarray analysis, polymorphism analysis, tumor replication error analysis
- Genetic
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Cerebral Palsy, Mobile Phone Use, Pediatric ALL, Physical Disability, Physical Inactivity
- Interventions
- Augment Reality Exergames
- Device
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- Interventions
- BEAM-201
- Biological
- Lead sponsor
- Beam Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Stanford, California • Denver, Colorado • Chicago, Illinois + 7 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma, Sarcoma, Neuroblastoma
- Interventions
- Food Safety Guidelines, Neutropenic Diet
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 6
- States / cities
- San Diego, California • Indianapolis, Indiana • Brooklyn, New York + 2 more
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
- Interventions
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
- Device · Drug
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Lymphomas, Bone Marrow Failure, Hemoglobinopathy, Immune Deficiency, Osteopetrosis, Cytopenias, Leukocyte Disorders, Anemia Due to Intrinsic Red Cell Abnormality
- Interventions
- CD34+ enriched, T Cell Depleted donor stem cell product
- Biological
- Lead sponsor
- Christopher Dvorak
- Other
- Eligibility
- 2 Months to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 1 Year to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Amarillo, Texas
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
- Interventions
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 99,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2041
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
- Interventions
- AC220, Cytarabine, Etoposide, Methotrexate
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Madera, California • San Francisco, California + 8 more
- Conditions
- Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma, Acute Lymphoblastic Leukemia ,Lymphomas
- Interventions
- my.naviGATE Digital Tool
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts